
PLRX Stock Forecast & Price Target
PLRX Analyst Ratings
Bulls say
Pliant Therapeutics is focused on advancing its lead product candidate, bexotegrast, a small molecule targeting integrins αvβ8 and αvβ1, which has shown signs of efficacy in treating idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The company is preparing to initiate a new Phase 2b dose-ranging study for bexotegrast in IPF, with the potential to optimize the drug's risk-benefit profile through targeted therapy that enhances safety. Given the encouraging preliminary data and the strategic approach to clinical development, Pliant Therapeutics presents a positive outlook for investors as it seeks to establish a strong market position within fibrosis treatment.
Bears say
Pliant Therapeutics has faced a significant setback with the discontinuation of the BEACON-IPF Phase 2b trial for its primary candidate, bexotegrast, due to a safety-related imbalance characterized by unexpectedly low adverse event rates in the placebo group. This interruption not only raises concerns regarding the long-term viability of bexotegrast for idiopathic pulmonary fibrosis but also highlights the company’s reliance on a thin pipeline, which lacks alternative therapeutic options for at least one year. Financially, Pliant reported a substantial net loss of $49.7 million for Q4 2024, further complicating its outlook amid the challenges with product development and limited prospects for advancing its drug candidates.
This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
PLRX Analyst Forecast & Price Prediction
Start investing in PLRX
Order type
Buy in
Order amount
Est. shares
0 shares